机构地区:[1]Department of Neurology,Peking Union Medical College Hospital,53 Dongdan N St,Dongcheng,Beijing,China [2]Department of Neurology,The First Affiliated Hospital of Guangzhou Medical University,Guangzhou,China [3]Department of Neurology,Ruijin Hospital,Shanghai Jiaotong University School of Medicine,Shanghai,China [4]Department of Neurology,The Second Affiliated Hospital of Soochow University,Suzhou,China [5]Department of Neurology,West China Hospital,Sichuan University,Chengdu,China [6]Department of Neurology,Renji Hospital,Shanghai Jiaotong University School of Medicine,Shanghai,China [7]Department of Neurology,Huashan Hospital,Fudan University,Shanghai,China [8]Department of Neurology,Tongji Hospital of Tongji Medical College,Huazhong University of Science and Technology,Wuhan,China [9]Department of Neurology,The First Affiliated Hospital of Xi’an Jiaotong University,Xi’an,China [10]Department of Neurology,Beijing Tiantan Hospital,Capital Medical University,Beijing,China [11]Department of Neurology,Beijing Hospital,Beijing,China [12]Department of Neurology,Peking University First Hospital,Beijing,China [13]Department of Neurology,The Second Affiliated Hospital of Guangzhou Medical University,Guangzhou,China [14]Department of Neurology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,China [15]Department of Neurology,The Second Affiliated hospital of Zhejiang University School of Medicine,Zhejiang,Hangzhou,China [16]Department of Neurology,Beijing Friendship Hospital,Capital Medical University,Beijing,China [17]Department of Neurology,Guangzhou First People’s Hospital,Guangzhou,China [18]Department of Neurology,Xijing Hospital,The First Affiliated Hospital of The Fourth Military Medical University,Xi’an,China
出 处:《Translational Neurodegeneration》2018年第1期127-137,共11页转化神经变性病(英文)
摘 要:Background:The use of adjunct rasagiline in levodopa-treated patients with Parkinson’s disease and motor fluctuations is supported by findings from large-scale clinical studies.This study is to investigate the efficacy and safety of adjunct rasagiline in Chinese patients with Parkinson’s disease,as a product registration study.Methods:This 16-week,randomized,double-blind,parallel-group,multicenter,placebo-controlled study of rasagiline 1 mg/day included levodopa-treated patients with Parkinson’s disease and motor fluctuations.The primary efficacy endpoint was mean change from baseline in total daily OFF time over 16 weeks.Secondary endpoints were Clinical Global Impressions–Improvement(CGI-I),and change in Unified Parkinson’s Disease Rating Scale(UPDRS)Activities of daily living(ADL)and Motor scores.Patient well-being(EQ-5D),and the frequency of adverse events were also assessed.Results:In total,324 levodopa-treated patients were randomized to rasagiline 1 mg/day(n=165)or placebo(n=159).Over 16 weeks,rasagiline statistically significantly reduced the mean[95% confidence interval]total daily OFF time versus placebo(−0.5 h[−0.92,−0.07];p=0.023).There were also statistically significant improvements versus placebo in CGI-I(−0.4 points[−0.61,−0.22];p<0.001),UPDRS-ADL OFF(−1.0 points[−1.75,−0.27];p=0.008),and UPDRS-Motor ON(−1.6 points[−3.05,−0.14];p=0.032)scores,as well as the EQ-5D utility index(p<0.05).Rasagiline was safe and well tolerated.Conclusions:In levodopa-treated Chinese patients with Parkinson’s disease and motor fluctuations,adjunct rasagiline 1 mg/day statistically significantly reduced OFF time,and improved daily function and overall well-being,versus placebo.Consistent with findings in other countries,adjunct rasagiline was proven efficacious and well tolerated in Chinese patients.
关 键 词:Parkinson’s disease RASAGILINE ADJUNCT Motor fluctuations OFF time Quality of life China
分 类 号:R74[医药卫生—神经病学与精神病学]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...